Washington Examiner
Sign in Subscribe
News
Politics
White House
Senate
House
Campaigns
Business
World
Investigations
Justice
Supreme Court
Crime
Entertainment
Washington Secrets
Policy
Defense
National Security
Energy and Environment
Education
Immigration
Finance and Economy
Healthcare
Foreign Policy
Tech
Infrastructure
Space
2026 Election
America at 250
IN FOCUS
Commentary
Columnists
Editorials
Think Tanks
Beltway Confidential
Op-Eds
Restoring America
Patriotism and Unity
Faith, Freedom, and Self-Reliance
Courage, Strength, and Optimism
Equality, Not Elitism
Community and Family
Fairness and Justice
Mission
Watch
Magazine
Magazine
Quarterly Briefing
Archives
Games
Sponsored
Protecting Air Ambulance Services
Powering Progress
ASAE – Association Leadership
National Parks
Examining Tax Reform
Fix TSCA
Inside the Corn Belt
Examining Transportation
Newsletters
Sign In Sign InHome
News
Politics
Policy2026 Election
Opinion
EditorialsOp-Eds
In FocusRestoring AmericaMagazineWatch
Sponsored
Protecting Air Ambulance ServicesPowering ProgressASAE – Association LeadershipNational ParksExamining Tax ReformFix TSCAInside the Corn BeltExamining Transportation
TWS Archive
Advertisement
Home › Authors › Posts by Matthew Perrone

Matthew Perrone

Read the latest stories and analysis from Matthew Perrone.

News

FDA approves first pre-surgical breast cancer drug

Matthew Perrone · September 30, 2013 2:11 pm
Healthcare

FDA requires tracking codes on medical implants

Matthew Perrone · September 20, 2013 6:48 pm
This undated photo provided by Roche, shows the initial treatment drug Perjeta The U.S. Food and Drug Administration has issued a positive review of Perjeta, a breast cancer drug from Roche that could soon become the first pharmaceutical option approved for treating early-stage disease before surgery. (AP Photo/Roche) Healthcare

FDA panel backs drug for early stage breast cancer

Matthew Perrone · September 12, 2013 9:23 pm
This undated photo provided by Roche, shows the initial treatment drug Perjeta The U.S. Food and Drug Administration has issued a positive review of Perjeta, a breast cancer drug from Roche that could soon become the first pharmaceutical option approved for treating early-stage disease before surgery. (AP Photo/Roche) News

FDA: Roche drug works in early-stage breast cancer

Matthew Perrone · September 10, 2013 9:20 pm
News

FDA orders starker warnings on opioid painkillers

Matthew Perrone · September 10, 2013 9:16 pm
News

J&J recalls Infant Motrin due to plastic specks

Matthew Perrone · September 6, 2013 10:41 pm
News

Chobani says mold in yogurt does not carry disease

Matthew Perrone · September 6, 2013 6:33 pm
This undated product image provided by Johnson & Johnson shows a bottle of Extra Strength Tylenol bearing a new warning label on the cap alerting users to potentially fatal risks of taking too much of the pain reliever. Johnson & Johnson, the company that makes Tylenol, says the warning will appear on the cap of new bottles of Extra Strength Tylenol sold in the U.S. starting in October 2013 and on most other Tylenol bottles in coming months. (AP Photo/Johnson & Johnson) News

J&J launches new cap to curb Tylenol overdoses

Matthew Perrone · August 29, 2013 10:39 pm
Business

FDA approves new silicone breast implant from J&J

Matthew Perrone · June 14, 2013 8:53 pm
News

FDA finds fungus in drugs from Tennessee pharmacy

Matthew Perrone · June 7, 2013 9:30 pm
Business

Weight loss drug Belviq gets overdue US launch

Matthew Perrone · June 7, 2013 3:39 pm
Business

FDA panel favors easing safety limits on Avandia

Matthew Perrone · June 6, 2013 10:35 pm
Advertisement
  • ‹Previous page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 13
  • ›Next page
Page 8 of 13
Advertisement
Washington Examiner Manage Preferences

News

  • Politics
    • White House
    • Senate
    • House
    • Campaigns
  • Business
  • World
  • Investigations
  • Justice
  • Supreme Court
  • Crime
  • Washington Secrets
  • Entertainment
  • Sports

Policy

  • Defense
  • National Security
  • Energy
  • Immigration
  • Finance and Economy
  • Healthcare
  • Foreign Policy
  • Tech
  • Infrastructure
  • Space

Commentary

  • Columnists
  • Editorials
  • Think Tanks
  • Beltway Confidential
  • Op-Eds

Restoring America

  • Patriotism & Unity
  • Faith, Freedom & Self-Reliance
  • Courage, Strength & Optimism
  • Equality, Not Elitism
  • Community & Family
  • Fairness & Justice
  • Mission

Watch

  • Shows
NEWSLETTERS MAGAZINE ARCHIVE
  • Policies and Standards
  • Terms Of Service
  • Subscription Terms of Use
  • Privacy Policy
  • Your Privacy Choices
  • Transparency In Coverage
  • Advertise
  • Subscribe
  • Contact
  • Careers
  • Staff
  • About Examiner
  • Facebook
  • Twitter
© Copyright 2026. Washington Examiner. All Rights Reserved.
Advertisement